Key Points of Dr. Reddy’s Laboratories Hypertension Injection Launch:
- Dr. Reddy’s Laboratories launched Treprostinil injection in the US market, a therapeutic equivalent generic version of Remodulin.
- Treprostinil injection relaxes blood vessels and increases the supply of blood to the lungs, used for treating pulmonary arterial hypertension.
- The USFDA has approved the injection, and clinical studies have shown its effectiveness in patients with NYHA Functional Class II-IV.
- The most common side effects of the drug are subcutaneous infusion site pain and reaction, headache, diarrhea, nausea, jaw pain, vasodilatation, edema, and hypotension.
- Dr. Reddy’s recently appointed actor and philanthropist Sonu Sood as its brand ambassador for its ready-to-serve fruit beverage segment Rebalanz Vitors.
- Eris Lifesciences acquired nine dermatology brands from Dr. Reddy’s for Rs 275 crore last month.
- Dr. Reddy’s Q3 earnings report showed consolidated revenue of Rs 6,790 crore, up 27.2% YoY, with new products and increasing volumes contributing significantly. PAT rose by 75.4% YoY to Rs 1,244 crore.
Details of Dr. Reddy’s Laboratories Hypertension Injection Launch:
Dr. Reddy’s Laboratories Ltd., a leading pharmaceutical company, announced on Friday the launch of Treprostinil injection in the US market, along with its subsidiaries. The US Food and Drug Administration (USFDA) has approved the injection, which is a therapeutic equivalent generic version of Remodulin. This injection works by relaxing blood vessels and increasing the supply of blood to the lungs.
Treprostinil injection is classified as a prostacyclin mimetic and is used to treat pulmonary arterial hypertension by reducing symptoms associated with exercise. Clinical studies have shown its effectiveness in patients with NYHA Functional Class II-IV (mild shortness of breath) symptoms. The most common side effects of the drug, reported in clinical studies, are subcutaneous infusion site pain and reaction, headache, diarrhea, nausea, jaw pain, vasodilatation, edema, and hypotension.
In other news, Dr. Reddy’s recently appointed actor and philanthropist Sonu Sood as its brand ambassador for its ready-to-serve fruit beverage segment Rebalanz Vitors. Eris Lifesciences also acquired nine dermatology brands from Dr. Reddy’s for Rs 275 crore last month. On April 5, the company’s shares hit a fresh 52-week high.
According to Dr. Reddy’s quarter three earnings report released in December, the company’s consolidated revenue for the quarter stood at Rs 6,790 crore, up 27.2 percent from the previous year’s quarter. The introduction of new products and increasing volumes contributed significantly to this revenue surge. Compared to a year ago, the company’s profit after tax (PAT) increased by a significant 75.4 percent to Rs 1,244 crore.
About Dr. Reddy’s Laboratories:
Dr. Reddy’s Laboratories, a multinational pharmaceutical company, has its headquarters in Hyderabad, India. The company’s founder is Kallam Anji Reddy, who previously worked at the Indian Drugs and Pharmaceuticals Limited mentor institute.
For More Latest News Click Here
